InChi Code: InChI=1S/C62H98N16O22.C2H4O2/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64,1-2(3)4/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100),1H3,(H,3,4)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-,/m0./s1
(3) Moreover, where extended immobilization is required, such as during recovery from a hip fracture, serious co-morbidities can emerge, including: unintentional injuries, diseases of the heart, vascular embolisms, chronic lower respiratory infections, and even death
Thus, protective Ab responses effectively exclude large portions of the population from benefitting from gene therapy
Optimal balance: 2.4mg weekly emerged as best efficacy-to-tolerability ratio
10.1016/j.lwt.2024.116083 243 RoversiD.TroianoC.SalnikovE.GiordanoL.RiccitelliF.De ZottiM.et al (2023)